跳至主要内容
临床试验/NCT07260006
NCT07260006招募中不适用

A Study on the Treatment Efficacy of Regimens With and Without Bismuth in Children With Helicobacter Pylori-Associated Peptic Ulcer Disease

Can Tho University of Medicine and Pharmacy1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2024年10月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
80
试验地点
1
主要终点
Eradication rate of Helicobacter pylori infection between the two treatment regimens

研究概览

简要总结

The goal of this clinical trial is to learn if including bismuth in the treatment helps heal stomach and duodenal ulcers caused by Helicobacter pylori (H. pylori) in children.

The main questions it aims to answer are:

  • Does a treatment plan with bismuth work better than a plan without bismuth to clear the infection?
  • Is the bismuth plan more cost-effective while still safe and effective?

Researchers will compare two treatment groups to see which works better. Participants will:

  • Take one of the two assigned treatment plans (with or without bismuth) for the standard treatment duration
  • Visit the clinic for checkups and tests to confirm infection clearance and monitor side effects
  • Keep a diary of symptoms, medication use, and any side effects

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
5 Years 至 15 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Diagnosed with gastritis or peptic ulcer disease by upper gastrointestinal endoscopy or histopathology.
  • Meets diagnostic criteria for Helicobacter pylori infection.
  • Parent or legal guardian provides consent for the child to participate in the study.

排除标准

  • Allergic to any of the medications in the treatment regimen.
  • Use of antibiotics or bismuth within the past 4 weeks, or use of antacids, H2-receptor antagonists, or proton pump inhibitors within the past 2 weeks.
  • Failure to return for follow-up visits after treatment.

研究组 & 干预措施

Bismuth quadruple therapy

Experimental

Patients in this arm will receive PPI, Amoxicillin, Metronidazole, and Bismuth for 14 days, with doses adjusted according to weight and age.

干预措施: Bismuth quadruple therapy (Drug)

Triple therapy with PPI + Amoxicillin + Metronidazole

Experimental

Patients in this arm will receive PPI, Amoxicillin, Metronidazole for 14 days, with doses adjusted according to weight and age.

干预措施: Triple therapy with PPI + Amoxicillin + Metronidazole (Drug)

结局指标

主要结局

Eradication rate of Helicobacter pylori infection between the two treatment regimens

时间窗: Two weeks after discontinuation of acid suppression therapy following completion of the eradication regimen.

The efficacy of the two regimens will be evaluated by comparing H. pylori eradication rates. Clinical examination and a urea breath test or stool antigen test will be performed after completion of therapy to confirm eradication. Patients will receive a 14-day treatment regimen, followed by an additional 2-4 weeks of proton pump inhibitor (PPI) therapy to promote healing of gastric or duodenal lesions.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Mai Thùy Trang

Doctor

Can Tho University of Medicine and Pharmacy

研究点 (1)

Loading locations...

相似试验